The C-WORTHY trial is a randomised , open-label phase 2 trial of grazoprevir plus elbasvir with or without ribavirin ; here we report findings for two cohorts of previously untreated patients with cirrhosis ( cohort 1 ) and those with previous PR-null response with or without cirrhosis ( cohort 2 ) enrolled in part B of the study .